P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions

Oxaliplatin (OXA)-containing regimens are used as first-line chemotherapy in colorectal cancer (CRC). However, OXA resistance remains a major challenge in CRC treatment. CRC cells that adapt to hypoxia can potentially develop OXA resistance, and the underlying molecular mechanisms still need to be f...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiayu, Li, Chenguang, Sun, Luanbiao, Sun, Denghua, Zhao, Tiancheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636723/
https://www.ncbi.nlm.nih.gov/pubmed/37921068
http://dx.doi.org/10.3892/or.2023.8656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636723/
https://www.ncbi.nlm.nih.gov/pubmed/37921068
http://dx.doi.org/10.3892/or.2023.8656

Ejemplares similares